WALTHAM, Mass., April 28, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report first quarter 2008 results on Monday, May 5, 2008. A conference call and webcast will begin at 2:00 p.m. EDT (11:00 a.m. PDT), hosted by OXiGENE's President and Chief Executive Officer, Dr. Richard Chin; Chief Scientific Officer, Dr. David Chaplin; Chief Medical Officer, Dr. Patricia Walicke; Chief Business Officer, John Kollins and Chief Financial Officer, James Murphy.
To listen to a live or an archived version of the audio webcast, please log on to the Company's website, www.oxigene.com. Under the "Investor Center" tab, select the link to "Presentations & Conference Calls."
OXiGENE's earnings conference call can also be heard live by dialing (888) 656-7434 in the United States and Canada, and (913) 312-0659 for international callers, five minutes prior to the beginning of the call. A replay will be available starting at 5:00 p.m., EDT (2:00 p.m., PDT) on May 5, 2008 and ending at 5:00 p.m. EDT (2:00 p.m., PDT) on Monday, May 12, 2008. To access the replay, please dial (888) 203-1112 if calling from the United States or Canada, or (719) 457-0820 from international locations. Please refer to replay pass code 1450115.
About OXiGENE
OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The company's major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.
The OXiGENE, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=4969